135 related articles for article (PubMed ID: 37353942)
1. The prognosis of fibrolamellar carcinoma versus conventional hepatocellular carcinoma: a study based on propensity score matching.
Qiu S; Chen R; Hu J; Han T
Scand J Gastroenterol; 2023; 58(11):1351-1358. PubMed ID: 37353942
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma.
Yamashita S; Vauthey JN; Kaseb AO; Aloia TA; Conrad C; Hassan MM; Passot G; Raghav KP; Shama MA; Chun YS
J Gastrointest Surg; 2016 Oct; 20(10):1725-31. PubMed ID: 27456016
[TBL] [Abstract][Full Text] [Related]
3. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective.
Mayo SC; Mavros MN; Nathan H; Cosgrove D; Herman JM; Kamel I; Anders RA; Pawlik TM
J Am Coll Surg; 2014 Feb; 218(2):196-205. PubMed ID: 24315886
[TBL] [Abstract][Full Text] [Related]
4. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study.
El-Serag HB; Davila JA
Hepatology; 2004 Mar; 39(3):798-803. PubMed ID: 14999699
[TBL] [Abstract][Full Text] [Related]
5. Management and survival for patients with stage-I hepatocellular carcinoma: An observational study based on SEER database.
Wu Z; Chen W; Ouyang T; Liu H; Cao L
Medicine (Baltimore); 2020 Oct; 99(41):e22118. PubMed ID: 33031259
[TBL] [Abstract][Full Text] [Related]
6. Postoperative survival analysis of hepatocellular carcinoma patients with liver cirrhosis based on propensity score matching.
Wu Z; Tang H; Wang L; Jin X; Lei Z; Yang P; Zhou J
BMC Surg; 2022 Mar; 22(1):103. PubMed ID: 35313836
[TBL] [Abstract][Full Text] [Related]
7. Surgery versus external beam radiation therapy for AJCC stage I hepatocellular carcinoma.
Han B; Shao L; Li C; Xu Y; Tang Y; Han L; Qi X
J BUON; 2019; 24(4):1390-1401. PubMed ID: 31646782
[TBL] [Abstract][Full Text] [Related]
8. Long-term oncological prognosis after curative-intent liver resection for hepatocellular carcinoma in the young versus the elderly: multicentre propensity score-matching study.
Pu JL; Chen Z; Yao LQ; Feng JY; Diao YK; Guan MC; Li JD; Chen ZL; Zhou YH; Wang H; Gu WM; Li J; Li C; Wang MD; Zhu H; Liang YJ; Shen F; Pawlik TM; Lau WY; Yang T
BJS Open; 2022 Jan; 6(1):. PubMed ID: 35086147
[TBL] [Abstract][Full Text] [Related]
9. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
10. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
[No Abstract] [Full Text] [Related]
11. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
Alshareefy Y; Shen CY; Prekash RJ
Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Patients with Scirrhous Hepatocellular Carcinoma: Insights from the National Cancer Database.
Farooq A; Merath K; Paredes AZ; Wu L; Tsilimigras DI; Hyer JM; Sahara K; Mehta R; Beal EW; Pawlik TM
J Gastrointest Surg; 2020 May; 24(5):1049-1060. PubMed ID: 31243715
[TBL] [Abstract][Full Text] [Related]
13. Comparison of survival between adolescent and young adult
Ren J; Tong YM; Cui RX; Wang Z; Li QL; Liu W; Qu K; Zhang JY; Liu C; Wan Y
World J Gastrointest Oncol; 2020 Dec; 12(12):1394-1406. PubMed ID: 33362910
[TBL] [Abstract][Full Text] [Related]
14. No significant relationship exists between tumor size and prognosis in distant metastatic hepatocellular carcinoma: a propensity score matching analysis based on SEER database.
Xie J; Zheng C; Xie J; Wang F; Liu D; Zeng R; Yu C; Chen S
BMC Gastroenterol; 2022 Jun; 22(1):274. PubMed ID: 35655184
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of surgical resection versus radiofrequency ablation in very-early-stage hepatocellular carcinoma: a propensity score matching analysis.
Li YC; Chen PH; Yeh JH; Hsiao P; Lo GH; Tan T; Cheng PN; Lin HY; Chen YS; Hsieh KC; Hsieh PM; Lin CW
BMC Gastroenterol; 2021 Nov; 21(1):418. PubMed ID: 34749663
[TBL] [Abstract][Full Text] [Related]
16. Competing risk model for prognostic comparison between clear cell type and common type hepatocellular carcinoma: A population-based propensity score matching study.
Zhong X; Hu X; Fan XG
Cancer Med; 2023 May; 12(9):10406-10422. PubMed ID: 36934433
[TBL] [Abstract][Full Text] [Related]
17. Elevated Serum α-Fetoprotein is Associated with Abbreviated Survival for Patients with Fibrolamellar Hepatocellular Carcinoma Who Undergo a Curative Resection.
McDonald JD; Gupta S; Shindorf ML; Gamble LA; Ruff SM; Drake J; Heller T; Wan JY; Dickson PV; Glazer ES; Davis JL; Deneve JL; Hernandez JM
Ann Surg Oncol; 2020 Jun; 27(6):1900-1905. PubMed ID: 31925595
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis.
Lin CW; Wu TC; Lin HY; Hung CM; Hsieh PM; Yeh JH; Hsiao P; Huang YL; Li YC; Wang YC; Shu CW; Chen YS
BMC Gastroenterol; 2021 Jan; 21(1):20. PubMed ID: 33413162
[TBL] [Abstract][Full Text] [Related]
19. Impact of perioperative allogeneic blood transfusion on the long-term prognosis of patients with different stage tumors after radical resection for hepatocellular carcinoma.
Peng T; Wang L; Cui H; Li X; Liu M; Yu J; Wu J; Zhao G; Liu Z
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):620-627. PubMed ID: 32988700
[TBL] [Abstract][Full Text] [Related]
20. Validation of a supplementary condition of eighth AJCC staging system for stage II hepatocellular carcinoma.
Li M; Wu L; Luo S; Liu Y; Sun C; Li E; Wang J; Li B; Huang Z; Ge J; Lei J; Zhou F; Liao W
Eur J Surg Oncol; 2023 Jul; 49(7):1217-1225. PubMed ID: 36690533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
